Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2233–2256 of 3,534 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Saline (Placebo Control) Clear all

Conditions: Post-operative Pain
Interventions: Placebo, IV acetaminophen; Drug
Lead sponsor: Aultman Health Foundation; Other
Eligibility: 18 Years to 85 Years · Female only
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Canton, Ohio

Conditions: Healthy
Interventions: Ad26.Filo, MVA-BN-Filo, Ad26.ZEBOV, Placebo; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Pelvic Girdle Pain
Interventions: Corticosteroid, Placebo Injection; Drug
Lead sponsor: Loyola University; Other
Eligibility: 21 Years to 50 Years · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Psoriatic Arthritis
Interventions: Abatacept, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 19
States / cities: Huntsville, Alabama • Palm Desert, California • Palo Alto, California + 16 more

Conditions: Prurigo Nodularis
Interventions: CDX-0159, Normal saline; Biological · Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 7
States / cities: Tempe, Arizona • Miami, Florida • Troy, Michigan + 4 more

Conditions: Traumatic Brain Injury
Interventions: Ovidrel, Placebo; Drug · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Rheumatoid Arthritis
Interventions: Placebo, Certolizumab pegol; Other · Biological
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 41
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 38 more

Conditions: Rhinosinusitis, Chronic Eosinophilic Rhinosinusitis, Allergic Rhinosinusitis
Interventions: Budesonide, Saline alone; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 70 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Sleep Deprivation, Pain
Interventions: Morphine, Saline Placebo, Forced Awakenings, Uninterrupted Sleep; Drug · Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 48 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: STEMI, STEMI (ST Elevation MI), STEMI - ST Elevation Myocardial Infarction (MI), Stent Implantation
Interventions: Atibuclimab (IC14), 20 mg/kg intravenously, once, Placebo, 150 mL intravenously, once; Drug · Other
Lead sponsor: Implicit Bioscience; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: St Louis, Missouri • Charlottesville, Virginia

Conditions: COVID-19, SARS-CoV-2
Interventions: AZD5156 (Parent study Sentinel Safety Cohort), Placebo (Parent study Sentinel Safety Cohort), EVUSHELD™ (Parent study Main Cohort), AZD3152 (Parent study Main Cohort), Placebo (Parent study Main Cohort), AZD3152 (Sub-study), AZD7442 - EVUSHELD™ (Sub-study), AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 130 Years
Enrollment: 3,882 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 130
States / cities: Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 108 more

Conditions: Influenza
Interventions: Aluminum hydroxide, Inactivated Vero cell based whole virus influenza A/H5N1, Placebo; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 308 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 5
States / cities: Stanford, California • Torrance, California • Baltimore, Maryland + 2 more

Conditions: Safety and Tolerability in Healthy Subjects
Interventions: BNZ132-1-40, Placebo; Drug
Lead sponsor: Bioniz Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Diabetes Mellitus, Type 1, Diabetes type1, Autoimmune Diabetes
Interventions: Bacillus Calmette-Guérin, Saline Injection; Biological
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 8 Years to 17 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Type 2 Diabetes
Interventions: Duodenal Mucosal Resurfacing (DMR), Duodenal Mucosal Resurfacing Sham (Sham); Device
Lead sponsor: Fractyl Health Inc.; Industry
Eligibility: 28 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 6
States / cities: Orlando, Florida • Boston, Massachusetts • Lebanon, New Hampshire + 3 more

Conditions: Type 1 Diabetes
Interventions: Denosumab, Placebo; Drug · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 50 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Birmingham, Alabama • Duarte, California • Indianapolis, Indiana

Conditions: Preterm Birth
Interventions: 17-alpha-hydroxyprogesterone caproate injectable, Placebo; Drug
Lead sponsor: Obstetrix Medical Group; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 321 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 18
States / cities: Phoenix, Arizona • Tucson, Arizona • Laguna Hills, California + 13 more

Conditions: Influenza (Pandemic)
Interventions: Monovalent Avian Influenza VLP (H5N1), Monovalent Avian Influenza VLP (H5N1); Adjuvant, Saline placebo; Biological
Lead sponsor: Novavax; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 333 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 5
States / cities: Anaheim, California • Miami, Florida • Pembroke Pines, Florida + 2 more

Conditions: Critical Illness, Depressive Symptoms
Interventions: Ketamine (0.5 mg/kg), Normal Saline (0.9% NaCl); Drug · Other
Lead sponsor: Hospital Italiano de Buenos Aires; Other
Eligibility: 18 Years to 99 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Presbyopia
Interventions: PRX-100, Placebo; Drug
Lead sponsor: LENZ Therapeutics, Inc; Other
Eligibility: 45 Years to 59 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Respiratory Syncytial Virus Infections
Interventions: ALN-RSV01, normal saline; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 10
States / cities: San Diego, California • San Francisco, California • Denver, Colorado + 7 more

Conditions: Acute Myocardial Infarction, Moderate Renal Impairment
Interventions: CSL_112, Placebo; Biological · Other
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 13
States / cities: Birmingham, Alabama • Huntsville, Alabama • Concord, California + 10 more

Conditions: Uterine Atony, Uterine Atony With Hemorrhage, Cesarean Section Complications
Interventions: Calcium Chloride, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Stanford, California

Conditions: Traumatic Rib Fracture(s)
Interventions: Cryoneurolysis with a Painblocker (Epimed International, Farmers Branch, Texas), Intercostal nerve block ropivacaine with epinephrine, Sham cryoneurolysis with a Painblocker, Placebo intercostal nerve block with normal saline; Device · Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: San Diego, California

Search by objective public record fields.

Efficacy of IV Acetaminophen for Pain Management

A Study to Evaluate Safety, Tolerability, and Immunogenicity of Heterologous Prime-boost Regimens Using the Multivalent Filovirus Vaccines Ad26.Filo and MVA-BN-Filo Administered in Different Sequences and Schedules in Healthy Adults

Ultrasound Guided Posterior Sacroiliac Ligament Corticosteroid Injection in Pregnancy-Related Pelvic Girdle Pain

Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis

A Study of CDX-0159 in Patients With Prurigo Nodularis

hCG Treatment for Rehabilitation From a TBI

Assessing the Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis on the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines

The Impact Of The Addition Of Budesonide To Low-Pressure, High-Volume Saline Sinus Irrigation For Chronic Rhinosinusitis

Mechanisms of Sleep Disruption Hyperalgesia

Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI

Parent Study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA Sub-study)

Dose-Escalating Trial Using Vero Cell-culture Derived H5N1 +/- Aluminum in Adults

A Multiple-Dose Study of Intravenous BNZ132-1-40 in Healthy Adult Subjects

Repeat BCG Vaccinations For The Treatment Of Pediatric Type 1 Diabetes

Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes

Denosumab for Type 1 Diabetes

17OHP for Reduction of Neonatal Morbidity Due to Preterm Birth (PTB) in Twin and Triplet Pregnancies

A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 1

Subanesthetic Ketamine Infusions for Depressive Symptoms in Intensive Care Unit Patients

Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia

Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)

A Study of CSL112 in Adults With Moderate Renal Impairment and Acute Myocardial Infarction

Calcium Chloride for Prevention of Uterine Atony During Cesarean

Rib Fracture Analgesia Using Cryoanalgesia